CA3161806A1 - Aliphatic acid amide derivative - Google Patents
Aliphatic acid amide derivative Download PDFInfo
- Publication number
- CA3161806A1 CA3161806A1 CA3161806A CA3161806A CA3161806A1 CA 3161806 A1 CA3161806 A1 CA 3161806A1 CA 3161806 A CA3161806 A CA 3161806A CA 3161806 A CA3161806 A CA 3161806A CA 3161806 A1 CA3161806 A1 CA 3161806A1
- Authority
- CA
- Canada
- Prior art keywords
- mhz
- nmr
- art
- tti
- cdc13
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-232927 | 2019-12-24 | ||
| JP2019232927 | 2019-12-24 | ||
| PCT/JP2020/048117 WO2021132311A1 (ja) | 2019-12-24 | 2020-12-23 | 脂肪族酸アミド誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3161806A1 true CA3161806A1 (en) | 2021-07-01 |
Family
ID=76574184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3161806A Pending CA3161806A1 (en) | 2019-12-24 | 2020-12-23 | Aliphatic acid amide derivative |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12503463B2 (https=) |
| EP (1) | EP4082616B1 (https=) |
| JP (1) | JP7662534B2 (https=) |
| KR (1) | KR20220120625A (https=) |
| CN (1) | CN114981264B (https=) |
| AU (1) | AU2020413284A1 (https=) |
| BR (1) | BR112022011844A2 (https=) |
| CA (1) | CA3161806A1 (https=) |
| ES (1) | ES3040677T3 (https=) |
| HU (1) | HUE072877T2 (https=) |
| MX (1) | MX2022007947A (https=) |
| PL (1) | PL4082616T3 (https=) |
| PT (1) | PT4082616T (https=) |
| WO (1) | WO2021132311A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220120625A (ko) * | 2019-12-24 | 2022-08-30 | 스미토모 파마 가부시키가이샤 | 지방족 산 아미드 유도체 |
| JP7655885B2 (ja) * | 2021-06-30 | 2025-04-02 | 住友ファーマ株式会社 | 脂肪族酸アミド誘導体を含有する医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880930A (en) | 1987-11-30 | 1989-11-14 | New James S | Psychotropic acyclic amide derivatives |
| EP0732332B1 (en) | 1995-03-17 | 2001-12-19 | Aventis Pharmaceuticals Inc. | Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation |
| US5880121A (en) * | 1996-01-05 | 1999-03-09 | Hoechst Marion Roussel Inc. | 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof |
| JP4497815B2 (ja) | 2001-02-16 | 2010-07-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用 |
| FR2827287B1 (fr) * | 2001-07-13 | 2003-10-31 | Servier Lab | Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2006508101A (ja) | 2002-11-08 | 2006-03-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | フェニルアルキルおよびピリジルアルキルピペラジン誘導体 |
| AU2006239302B2 (en) | 2005-04-26 | 2011-07-07 | Hypnion, Inc. | Benzisoxazole piperazine compounds and methods of use thereof |
| PL392436A1 (pl) | 2010-09-17 | 2012-03-26 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego |
| WO2014079155A1 (zh) * | 2012-11-26 | 2014-05-30 | 辽宁贝雷生物制药有限公司 | 苯并五元氮杂环基哌嗪或哌啶衍生物的用途 |
| KR20220120625A (ko) * | 2019-12-24 | 2022-08-30 | 스미토모 파마 가부시키가이샤 | 지방족 산 아미드 유도체 |
-
2020
- 2020-12-23 KR KR1020227025336A patent/KR20220120625A/ko active Pending
- 2020-12-23 PL PL20907330.3T patent/PL4082616T3/pl unknown
- 2020-12-23 CA CA3161806A patent/CA3161806A1/en active Pending
- 2020-12-23 JP JP2021567520A patent/JP7662534B2/ja active Active
- 2020-12-23 AU AU2020413284A patent/AU2020413284A1/en active Pending
- 2020-12-23 EP EP20907330.3A patent/EP4082616B1/en active Active
- 2020-12-23 MX MX2022007947A patent/MX2022007947A/es unknown
- 2020-12-23 US US17/612,099 patent/US12503463B2/en active Active
- 2020-12-23 HU HUE20907330A patent/HUE072877T2/hu unknown
- 2020-12-23 CN CN202080089588.6A patent/CN114981264B/zh active Active
- 2020-12-23 WO PCT/JP2020/048117 patent/WO2021132311A1/ja not_active Ceased
- 2020-12-23 PT PT209073303T patent/PT4082616T/pt unknown
- 2020-12-23 BR BR112022011844A patent/BR112022011844A2/pt unknown
- 2020-12-23 ES ES20907330T patent/ES3040677T3/es active Active
-
2021
- 2021-11-17 US US17/528,743 patent/US11339151B2/en active Active
-
2025
- 2025-11-18 US US19/392,712 patent/US20260078115A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12503463B2 (en) | 2025-12-23 |
| TW202136235A (zh) | 2021-10-01 |
| KR20220120625A (ko) | 2022-08-30 |
| EP4082616A1 (en) | 2022-11-02 |
| US20220073506A1 (en) | 2022-03-10 |
| US20260078115A1 (en) | 2026-03-19 |
| JPWO2021132311A1 (https=) | 2021-07-01 |
| BR112022011844A2 (pt) | 2022-08-30 |
| WO2021132311A1 (ja) | 2021-07-01 |
| EP4082616B1 (en) | 2025-09-03 |
| US11339151B2 (en) | 2022-05-24 |
| JP7662534B2 (ja) | 2025-04-15 |
| CN114981264A (zh) | 2022-08-30 |
| PL4082616T3 (pl) | 2025-12-15 |
| MX2022007947A (es) | 2022-07-27 |
| EP4082616A4 (en) | 2024-01-03 |
| AU2020413284A1 (en) | 2022-08-18 |
| US20220213079A1 (en) | 2022-07-07 |
| PT4082616T (pt) | 2025-12-02 |
| HUE072877T2 (hu) | 2025-12-28 |
| CN114981264B (zh) | 2024-07-26 |
| ES3040677T3 (en) | 2025-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3161806A1 (en) | Aliphatic acid amide derivative | |
| DE68920819T2 (de) | Antivirus-Verbindungen. | |
| AU762345B2 (en) | Aminophenoxyacetic acid derivatives as neuroprotectants | |
| US10214522B2 (en) | Anti-alphavbeta1 integrin inhibitors and methods of use | |
| DE69306298T2 (de) | Anticonvulsive Fructopyranose zyklische Sulfate und Sulfite | |
| CA2963639C (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| JP3208221B2 (ja) | １，５−イミノ糖類の２−および３−アミノおよびアジド誘導体類 | |
| CA2987570A1 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| CA3023465C (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| AU2006316087A1 (en) | Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I | |
| CA2841906A1 (en) | Azabenzimidazole derivative having ampk-activating activity | |
| DE1670265A1 (de) | 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung | |
| HUP0302526A2 (hu) | Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| CA2835705C (en) | Thiazole compounds, methods for preparation and use thereof | |
| CZ471190A3 (cs) | Inhibitory retrovirálních proteáz | |
| DE1922003A1 (de) | Aminosaeure-Derivate und Verfahren zur Herstellung derselben | |
| AU2011237072B2 (en) | Therapeutic agent or prophylactic agent for fibromyalgia | |
| CA2959293A1 (en) | Azaindole derivative having ampk-activating effect | |
| AU700805B2 (en) | Method for preparing N, N'-disubstitued cyclic ureas | |
| DE69303413T2 (de) | 2-substituierte-tertiäre-Carbinolderivate als antivirale Arzneimittel | |
| DK166823B1 (da) | Purinforbindelser, fremgangsmaade til fremstilling heraf, samt anvendelse af forbindelserne som farmaceutika | |
| HUP0200097A2 (hu) | Monoszacharidszármazékok mint sejtadhézió gátlók és az ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
| DE4126485A1 (de) | Trifluormethyl-haltige pseudopeptide | |
| Francisco et al. | Intramolecular 1, 5-hydrogen atom transfer reaction promoted by phosphoramidyl and carbamoyl radicals: synthesis of 2-amino-C-glycosides | |
| RO108869B1 (ro) | DERIVATI DE 6-ARIL-5,6-DIHIDROIMIDAZO-/2,1-b/-TIAZOL, PROCEDEU PENTRU PREPARAREA LOR SI INTERMEDIARI PENTRU REALIZAREA ACESTORA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241107 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241107 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241126 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241227 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241227 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250428 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251106 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251106 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251223 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260420 |